Literatur
-
1
The nocturnal oxygen therapy trial-NOTT .
Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia?.
Chest.
1980;
78
419-420
-
2
Anonymus .
Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.
Lancet.
1981;
1
681-686
-
3
The SUPPORT Principal Investigators .
A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT).
JAMA.
1995;
274
1591-1598
-
4
Anderson H R, Spix C, Medina S. et al .
Air pollution and daily admissions for chronic obstructive pulmonary disease in 6 European cities: results from the APHEA project.
Eur Respir J.
1997;
10
1064-1071
-
5
Anthonisen N R, Manfreda J, Warren C P. et al .
Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease.
Ann Intern Med.
1987;
106
196-204
-
6
Burge P S, Calverley P M, Jones P W. et al .
Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.
BMJ.
2000;
320
1297-1303
-
7
Chodosh S, McCarty J, Farkas S. et al .
Randomized, double-blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group.
Clin Infect Dis.
1998;
27
722-729
-
8
Crockett A J, Alpers J H, Moss J R.
Home oxygen therapy: an audit of survival.
Aust N Z J Med.
1991;
21
217-221
-
9
Dentener M A, Creutzberg E C, Schols A M. et al .
Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.
Thorax.
2001;
56
721-726
-
10 Global Initiative for Chronic Obstructive Lung Disease .Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop Report, Executive Summary. National Institutes of Health. National Heart, Lung, and Blood Institute. World Health Organisation 2001: 2701A
-
11
Griffiths T L, Phillips C J, Davies S. et al .
Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme.
Thorax.
2001;
56
779-784
-
12
Gulsvik A.
The global burden and impact of chronic obstructive pulmonary disease worldwide.
Monaldi Arch Chest Dis.
2001;
56
261-264
-
13
Moller A M, Villebro N, Pedersen T. et al .
Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial.
Lancet.
2002;
359
114-117
-
14
Saetta M, Di Stefano A, Maestrelli P. et al .
Airway eosinophilia and expression of interleukin-5 protein in asthma and in exacerbations of chronic bronchitis.
Clin Exp Allergy.
1996;
26
766-774
-
15
Sin D D, Tu J V.
Underuse of inhaled steroid therapy in elderly patients with asthma.
Chest.
2001;
119
720-725
-
16
Stockley R A, O'Brien C, Pye A. et al .
Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD.
Chest.
2000;
117
1638-1645
-
17
Vogel F, Worth H, Adam D. et al .
Rationale Therapie bakterieller Atemwegsinfektionen. Empfehlungen einer Expertengruppe der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. und der Deutschen Atemwegsliga e. V.
Chemotherapie Journal.
2000;
9
3-23
-
18
Winther B, Arruda E, Witek T J. et al .
Expression of ICAM-1 in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimental rhinovirus infection.
Arch Otolaryngol Head Neck Surg.
2002;
128
131-136
Priv.-Doz. Dr. med. G. Steinkamp
Klinische Forschung, Medizinisch-wissenschaftliches Publizieren
Schellingstr. 5a
30625 Hannover
Email: gratiana.steinkamp@t-online.de
